Table 1.
Baseline characteristics of the study population (n = 98).
| NLR | P | PLR | p | LMR | p | SII | p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <2.22 | ≥2.22 | <114.15 | ≥114.15 | <4.27 | ≥4.27 | <437.72 | ≥437.72 | |||||
| n (%) | n (%) | n (%) | n (%) | n(%) | n(%) | n(%) | n(%) | |||||
| Median age, years (range) | 53(26–83) | 53(26–78) | 0.872 | 53(26–83) | 52(26–78) | 0.741 | 57(28–77) | 50(26–83) | 0.084 | 52(26–83) | 54(28–78) | 0.367 |
| Gender | ||||||||||||
| Male | 25(51.0) | 34(69.4) | 0.063 | 27(55.1) | 32(65.3) | 0.302 | 29(59.2) | 30(61.2) | 0.836 | 26(53.1) | 33(67.3) | 0.149 |
| Female | 24(49.0) | 15(30.6) | 22(44.9) | 17(34.7) | 20(40.8) | 19(38.8) | 23(46.9) | 16(32.7) | ||||
| ECOG performance status | ||||||||||||
| 0 | 41(83.7) | 40(81.6) | 0.790 | 39(79.6) | 42(85.7) | 0.424 | 39(79.6) | 42(85.7) | 0.424 | 43(87.8) | 38(77.6) | 0.182 |
| 1–2 | 8(16.3) | 9(18.4) | 10(20.4) | 7(14.3) | 10(20.4) | 7(14.3) | 6(12.2) | 11(22.4) | ||||
| Tumor location | ||||||||||||
| Left colon | 17(34.7) | 16(32.7) | 0.914 | 15(30.6) | 18(36.7) | 0.810 | 16(32.7) | 17(34.7) | 0.969 | 15(30.6) | 18(36.7) | 0.139 |
| Right colon | 16(32.7) | 18(36.7) | 18(36.7) | 16(32.7) | 17(34.7) | 17(34.7) | 14(28.6) | 20(40.8) | ||||
| Rectum | 16(32.7) | 15(30.6) | 16(32.7) | 15(30.6) | 16(32.7) | 15(30.6) | 20(40.8) | 11(22.4) | ||||
| Clinical T stage a | ||||||||||||
| T1–2 | 5(13.5) | 4(9.3) | 0.726 | 3(8.1) | 6(14.0) | 0.494 | 4(9.5) | 5(13.2) | 0.729 | 5(12.8) | 4(9.8) | 0.734 |
| T3–4 | 32(86.5) | 39(90.7) | 34(91.9) | 37(86.0) | 38(90.5) | 33(86.8) | 34(87.2) | 37(90.2) | ||||
| Lymphnode metastasis a | ||||||||||||
| No | 9(24.3) | 8(18.6) | 0.533 | 9(24.3) | 8(18.6) | 0.533 | 7(16.7) | 10(26.3) | 0.292 | 8(21.6) | 9(20.9) | 0.940 |
| Yes | 28(75.7) | 35(81.4) | 28(75.7) | 35(81.4) | 35(83.3) | 28(73.7) | 29(78.4) | 34(79.1) | ||||
| Distant metastasis | ||||||||||||
| No | 39(79.6) | 19(38.8) | <0.001 | 38(77.6) | 20(40.8) | <0.001 | 16(32.7) | 42(85.7) | <0.001 | 40(81.6) | 18(36.7) | <0.001 |
| Yes | 10(20.4) | 30(61.2) | 11(22.4) | 29(59.2) | 33(67.3) | 7(14.3) | 9(18.4) | 31(63.3) | ||||
| Neoadjuvant chemotherapy regimen | ||||||||||||
| FOLFOX | 17(34.7) | 15(30.6) | 0.578 | 15(30.6) | 17(34.7) | 0.841 | 11(22.4) | 21(42.9) | 0.042 | 19(38.8) | 13(26.5) | 0.262 |
| XELOX | 25(51.0) | 23(46.9) | 24(49.0) | 24(49.0) | 30(61.2) | 18(36.7) | 20(40.8) | 28(57.1) | ||||
| FOLFIRI | 7(14.3) | 11(22.4) | 10(20.4) | 8(16.3) | 8(16.3) | 10(20.4) | 10(20.4) | 8(16.3) | ||||
| Pathological differentiation b | ||||||||||||
| Low grade | 4(16.7) | 6(20.0) | 1.000 | 5(20.0) | 5(17.2) | 1.000 | 3(10.0) | 7(29.2) | 0.089 | 4(16.0) | 6(20.7) | 0.736 |
| Intermediate to high grade | 20(83.3) | 24(80.0) | 20(80.0) | 24(82.8) | 27(90.0) | 17(70.8) | 21(84.0) | 23(79.3) | ||||
| LDH | ||||||||||||
| ≤220 | 47(95.9) | 46(93.9) | 1.000 | 46(93.9) | 47(95.9) | 0.382 | 44(89.8) | 49(100.0) | 0.056 | 48(98.0) | 45(91.8) | 1.000 |
| >220 | 2(4.1) | 3(6.1) | 3(6.1) | 2(4.1) | 5(10.2) | 0(0.0) | 1(2.0) | 4(8.2) | ||||
| CA 19-9 c | ||||||||||||
| ≤22 | 27(61.4) | 33(71.7) | 0.297 | 26(61.9) | 34(70.8) | 0.370 | 28(62.2) | 32(71.1) | 0.371 | 32(72.7) | 28(60.9) | 0.233 |
| >22 | 17(38.6) | 13(28.3) | 16(38.1) | 14(29.2) | 45(37.8) | 45(28.9) | 12(27.3) | 18(39.1) | ||||
| CA-125 d | ||||||||||||
| ≤35 | 35(97.2) | 38(97.4) | 1.000 | 35(100.0) | 38(95.0) | 0.495 | 33(97.1) | 40(97.6) | 1.000 | 36(97.3) | 37(97.4) | 1.000 |
| >35 | 1(2.8) | 1(2.6) | 0(0.0) | 2(5.0) | 1(2.9) | 1(2.4) | 1(2.7) | 1(2.6) | ||||
a80 were available, b54 were available, c90 were available, d75 were available.
NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, LMR lymphocyte-monocyte ratio, SII systemic immune-inflammation index, LDH lactic dehydrogenase, CA 19-9 carbohydrate antigen 19-9, CA-125 carbohydrate antigen-125.